Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer

Launched by FUDAN UNIVERSITY · Mar 28, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new technology called the EndoScell Scanner (ES) that helps doctors quickly and accurately assess the status of sentinel lymph nodes—important areas that can indicate whether breast cancer has spread. The trial aims to see how well this technology works compared to standard methods during surgery for patients with early-stage breast cancer. By using special fluorescent dyes that are safe and non-invasive, the ES can provide detailed images of cells in real-time, allowing for faster results and potentially better treatment planning.

To participate in this study, women aged 18 and older who have been diagnosed with breast cancer and are scheduled for a sentinel lymph node biopsy may be eligible. Participants will need to provide informed consent and must not have allergies to the study dyes or be pregnant or breastfeeding. During the trial, participants can expect to have their sentinel lymph nodes assessed using this new technology, which may help improve the accuracy of their surgical outcomes. The study is currently recruiting, and it's an exciting opportunity to explore a promising advancement in breast cancer treatment.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age 18 years and older (inclusive)
• • Female
• • Preoperative pathology confirmed invasive breast carcinoma or ductal carcinoma in situ
• • Scheduled for sentinel lymph node biopsy
• • Capable of and willing to provide informed consent
• Exclusion Criteria:
• • Patients with a confirmed allergy to methylene blue or sodium citrate tracers
• • Pregnant or lactating women
• • Patients unwilling to participate in the clinical study